Clinical Trial Update: The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5 [Phase 3]

View source ↗

Summary

A Phase 3 trial (PRIMO II) evaluated paricalcitol injections for renal failure–induced cardiac morbidity in CKD Stage 5 patients. The study was terminated, and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Left Ventricular Hypertrophy

Drugs mentioned

• Paricalcitol (Zemplar) (paricalcitol)

Snippet

Sponsor: Abbott | Conditions: Chronic Kidney Disease (CKD) Stage 5, Hypertrophy, Left Ventricular | Phase 3 | Status: TERMINATED | Results posted: 2010-08-04